Phosphatidylserine
Phosphatidylserine scored 7.1 / 10 (💪 Strong recommend) on the BioHarmony scale as a Nutrient supplement (phospholipid for neuronal membrane support).
Phosphatidylserine is a targeted phospholipid supplement with its best evidence in older adults with memory complaints and stress-linked cortisol regulation. The 1991 Crook AAMI trial used 300 mg/day, while newer sunflower and soy PS evidence is more mixed, including a mostly null 2025 healthy-child RCT.
What is Phosphatidylserine?
Phosphatidylserine (PS) is a phospholipid concentrated in cell membranes, especially neuronal membranes. It helps organize membrane proteins, synaptic signaling, vesicle release, and stress-hormone feedback. In plain English, PS is part of the "surface architecture" that lets brain cells communicate cleanly.
The strongest clinical case is not "everyone gets smarter." It is narrower: older adults with memory complaints, people with high stress reactivity, some children with ADHD-like inattention, and athletes using PS to blunt training-related cortisol. The classic memory evidence used bovine cortex PS, including Crook 1991 and Cenacchi 1993. Modern products are usually soy or sunflower PS, and that shift matters because Jorissen 2001 found no significant cognitive benefit from soy-derived PS in 120 older adults.
The 2024-2026 update reinforces the targeted-use framing. Duan 2025 was positive in older adults with MCI, but the formula included PS, alpha-lipoic acid, ginkgo flavonoids, B vitamins, and folate, so PS cannot take full credit. Friling 2025 found no primary or secondary outcome differences in healthy children overall, though a lower-baseline subgroup improved on visuospatial memory errors. That is exactly the pattern to expect from PS: useful when a bottleneck exists, easy to overrate when it does not.
Terminology
For regulatory context, see FDA's qualified health claims letters and EFSA's 2011 PS cognition opinion.
- PS: Phosphatidylserine, an anionic phospholipid concentrated in neuronal cell membranes.
- S-PS: Soy-derived or sunflower-derived phosphatidylserine, the modern commercial form.
- BC-PS: Bovine cortex phosphatidylserine, the brain-derived form used in many older cognition trials and discontinued commercially after BSE concerns.
- PS-DHA: Phosphatidylserine with DHA-rich omega-3 fatty acids attached or co-administered, used to better approximate brain-like phospholipid composition.
- HPA axis: Hypothalamic-pituitary-adrenal axis, the body's main stress-response system.
- ACTH: Adrenocorticotropic hormone, the pituitary signal that tells adrenal glands to release cortisol.
- Cortisol: A glucocorticoid stress hormone. Helpful acutely, harmful when chronically elevated.
- AAMI: Age-associated memory impairment, a research category for memory decline in older adults that does not meet dementia criteria.
- MCI: Mild cognitive impairment, a clinical state between normal cognition and dementia.
- ADHD: Attention-deficit/hyperactivity disorder. PS has adjunctive pediatric trial evidence, mainly for inattention.
- PKC: Protein kinase C, a signaling enzyme that uses PS-rich membranes as part of its activation surface.
- Akt: A cell-survival and signaling pathway influenced by PS membrane localization.
- GR: Glucocorticoid receptor, a cortisol receptor involved in stress-feedback regulation.
- TSST: Trier Social Stress Test, a standardized lab stressor used to test HPA-axis reactivity.
- Qualified health claim: FDA label language allowed when evidence is credible but not conclusive.
- EFSA: European Food Safety Authority, which applies a stricter health-claim standard than FDA qualified claims.
- WADA: World Anti-Doping Agency. PS is not a named banned substance, but supplement contamination remains an athlete risk.
How do you take Phosphatidylserine?
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 4 routes and 5 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral capsule | Soy-derived or sunflower-derived phosphatidylserine softgel or capsule | 100-300 mg/day for cognition; 400-800 mg/day for stress or exercise cortisol protocols | 100-400 mg/day for daily cognitive or stress stacks; 600-800 mg/day before demanding training or acute stress |
| Oral powder | Bulk PS powder, usually soy or sunflower lecithin-derived | Same as capsules: 100-300 mg/day cognition, 400-800 mg/day stress or exercise protocols | 100-600 mg/day mixed into food or drinks |
| PS + omega-3 complex | Marine PS-DHA or PS combined with DHA/EPA | 300 mg/day PS with attached or co-administered omega-3 fatty acids in memory and ADHD studies | 300 mg/day PS plus 1-2 g/day fish oil or algae DHA |
| Food-first intake | Egg yolk, soy lecithin, white beans, Atlantic mackerel, and organ meats | No clinical dose equivalence established | Dietary intake often estimated around 100-200 mg/day total PS |
Protocols
Older adult memory support Clinical
- Dose
- 300 mg/day total, split as 100 mg three times daily or 300 mg once daily with food
- Frequency
- Daily
- Duration
- Minimum 8-12 weeks; reassess after 12-24 weeks
Best aligned with [Crook 1991](https://pubmed.ncbi.nlm.nih.gov/2027477/) and [Cenacchi 1993](https://pubmed.ncbi.nlm.nih.gov/8323999/). Modern S-PS trials are more mixed, so combine with DHA if dietary omega-3 intake is low.
Stress reactivity / HPA-axis support Mixed
- Dose
- 400 mg/day with breakfast or lunch
- Frequency
- Daily
- Duration
- 2-3 weeks before evaluating
[Hellhammer 2004](https://doi.org/10.1080/10253890410001728379) used a soy lecithin phosphatidic acid and PS complex under a standardized stress test. Avoid late evening dosing if it causes wakefulness.
Exercise cortisol block Clinical
- Dose
- 600 mg/day for 10 days; optional acute pre-workout dose within the daily total
- Frequency
- Daily during heavy training blocks
- Duration
- 10 days to 4 weeks, then reassess
[Starks 2008](https://pubmed.ncbi.nlm.nih.gov/18662395/) reported lower peak cortisol and cortisol exposure after 10 days at 600 mg/day in a small crossover trial.
Pediatric ADHD adjunct Clinical
- Dose
- 200-300 mg/day, often with omega-3 fatty acids
- Frequency
- Daily
- Duration
- 8-15 weeks in trials
Use only with parent and clinician oversight. [Manor 2012](https://pubmed.ncbi.nlm.nih.gov/21807480/) used PS-omega-3; [Hirayama 2014](https://pubmed.ncbi.nlm.nih.gov/23495677/) used PS alone in a smaller study.
BC-PS approximation Mixed
- Dose
- 300 mg/day sunflower or soy PS plus DHA-containing omega-3
- Frequency
- Daily
- Duration
- 12-24 weeks
A practical workaround because bovine cortex PS is not commercially available. [Vakhapova 2010](https://pubmed.ncbi.nlm.nih.gov/20523044/) supports PS-DHA as a reasonable research direction, not proof that every PS plus fish-oil stack works.
Use-Case Specific Dosing
| Use Case | Dose | Notes |
|---|---|---|
How this score is calculated →
What are the benefits of Phosphatidylserine?
Upside contribution: 2.12
| Dimension | Weight | Band | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | Moderate | 0.750 | |
| Breadth | 15% | Moderate | 0.480 | |
| Evidence | 25% | Moderate | 0.850 | |
| Speed | 10% | Moderate | 0.320 | |
| Durability | 10% | Limited | 0.220 | |
| Bioindividuality | 15% | Moderate | 0.495 | |
| Total | 3.115 | |||
| Baseline offset (constant) | −1.000 | |||
| Effective upside contribution | 2.115 |
Dimensions are shown as a band rather than a decimal because repeat scoring of the same evidence moves a single dimension by up to 1 point. Hover or long-press a band to see the value it was scored at.
Upside Rationale
Efficacy. Phosphatidylserine produces real but moderate, responder-dependent effects rather than a transformative result, which is the honest real-world read. Crook 1991 treated 149 age-associated-memory-impairment patients with 300 mg/day bovine-cortex phosphatidylserine for 12 weeks and improved learning and memory-related performance versus placebo, while Cenacchi 1993 extended that elderly-cognition signal across a larger 6-month multicenter trial. Stress physiology is the other clear win: Starks 2008 lowered peak and total cortisol exposure after 600 mg/day for 10 days. The central limit on phosphatidylserine efficacy is source translation, because modern soy and sunflower phosphatidylserine are less consistently positive than the old bovine-cortex material those landmark trials actually used, so what you buy may underperform the studied effect.
Efficacy (Moderate): Phosphatidylserine produces small-to-moderate, responder-dependent effects, and the form a reader can actually buy performs worse than the landmark trials. Crook 1991 improved learning and memory in 149 age-associated-memory-impairment patients and Cenacchi 1993 extended that across 494 older adults, but both used bovine-cortex material withdrawn after the BSE era. On modern soy and sunflower phosphatidylserine the pattern is consistently weaker: Jorissen 2001 found no significant cognitive benefit in 120 older adults, Kato-Kataoka 2010 found no broad between-group signal, Friling 2025 was null across 209 healthy children, and Shen 2026 found phosphatidylserine failed to improve core ADHD symptoms while atomoxetine did.
Breadth of benefits (Moderate): Phosphatidylserine benefits span cognitive aging, memory, stress reactivity, exercise-cortisol blunting and pediatric inattention, but all of them trace back to a single root that Kim 2014 describes: neuronal membrane composition, protein kinase C and Akt scaffolding, synaptic vesicle function and HPA-axis feedback. That is a real multi-domain mechanism whose reach is largely mechanistic rather than independently demonstrated per domain, which is the band phosphatidylserine belongs in. The ADHD lane weakened directly with Shen 2026, and phosphatidylserine has essentially no evidence on metabolic, cardiovascular, skin, fertility, pain or mitochondrial endpoints despite being sold as a general brain supplement.
Evidence quality (Moderate): Phosphatidylserine carries a genuinely mixed signal, which is the band this lands in. Real replicated human trials exist for phosphatidylserine, including Cenacchi 1993 in 494 older adults, Vakhapova 2010 in 157, Manor 2012 in 200 children and the Lee 2021 meta-analysis, so phosphatidylserine is far above mechanism-only. The gap is source translation: the positive cognition and cortisol results used bovine-cortex material no longer sold, while soy-derived trials split between the null Jorissen 2001 and subgroup-only Kato-Kataoka 2010. Authority is split the same way, with a narrow FDA qualified claim, an EFSA rejection, and an Alzheimer's Association non-recommendation.
Speed of onset (Moderate): Phosphatidylserine moves a laboratory value quickly and the felt outcome slowly, which the ladder places in the one-to-three-week band. Starks 2008 measured reduced peak and total cortisol exposure after ten days at 600 mg per day, and mental-stress protocols with phosphatidylserine read out at two to three weeks. Cognition is much slower: the packet's structured field puts first noticeable change at eight weeks with full effect at twelve, Crook 1991 ran twelve weeks, Cenacchi ran six months and pediatric attention trials ran eight to fifteen weeks. The ladder explicitly discounts a fast signal that is a biomarker rather than something the person feels.
Durability (Limited): Phosphatidylserine is maintenance-dependent, which the ladder places in the band where most interventions land. The packet is explicit that plasma phosphatidylserine normalizes within days after stopping, cortisol effects fade over roughly one to two weeks, and cognitive changes are maintenance-dependent, with memory support persisting a few weeks at most before drifting toward baseline. No evidence in the packet shows a short course of phosphatidylserine producing lasting cognitive change after discontinuation, because the membrane and HPA-axis effects depend on continued incorporation and turnover like any other phospholipid. Reading the discontinuation sentence rather than the treatment-period sentence puts phosphatidylserine squarely in the gone-within-days-to-months band.
Bioindividuality (Moderate): Phosphatidylserine sits at the top of the roughly-half-respond band of the SM-066 ladder, credited for a real but soft predictor. Response to phosphatidylserine is strongly segmented: older adults with memory complaints, chronically stressed adults with high cortisol tone, athletes in heavy training blocks, children with inattention and people on low-phospholipid diets, while healthy users with normal memory and cortisol should expect little. Friling 2025 shows the pattern cleanly, with no whole-cohort benefit but a signal in children starting below median performance. Phosphatidylserine misses the majority-respond band because Jorissen 2001 found nothing even within the matched memory-impairment phenotype.
What are the risks & downsides of Phosphatidylserine?
Downside contribution: 0.48 (safety risks weighted extra)
| Dimension | Weight | Band | Visual | Weighted |
|---|---|---|---|---|
| Safety | 30% | Negligible | 0.390 | |
| Side effects | 15% | Low | 0.255 | |
| Cost premium | 5% | Low | 0.095 | |
| Effort | 5% | Negligible | 0.060 | |
| Opportunity | 5% | Low | 0.120 | |
| Dependency | 15% | Negligible | 0.180 | |
| Reversibility | 25% | Negligible | 0.275 | |
| Total | 1.375 | |||
| Harm subtotal × 1.4 | 1.540 | |||
| Opportunity subtotal × 1.0 | 0.275 | |||
| Combined downside | 1.815 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.475 |
Dimensions are shown as a band rather than a decimal because repeat scoring of the same evidence moves a single dimension by up to 1 point. Hover or long-press a band to see the value it was scored at.
Cost premium: premium over the cheapest legitimate route, not price.
Downside Rationale
Safety risk. Phosphatidylserine has a clean safety profile at nutritional doses, which is why this risk sits low. Cenacchi 1993 reported good tolerability across a 6-month elderly trial, and Vakhapova 2011 specifically evaluated the safety of phosphatidylserine-DHA in non-demented older adults. No serious drug interaction is established at normal supplement doses. The practical cautions for phosphatidylserine are soy allergy with soy-derived products, insufficient pregnancy data, concurrent anticoagulant or antiplatelet use without monitoring, and contamination risk for competitive athletes, who should check the WADA Prohibited List and choose third-party-tested phosphatidylserine. The bovine-versus-soy source question is mainly an efficacy issue here, not a safety one, since both modern forms are well tolerated.
Safety (Negligible): Phosphatidylserine has no plausible catastrophic mechanism, which is the benign floor band. Cenacchi 1993 reported good tolerability across a six-month elderly trial and Vakhapova 2011 was a dedicated safety evaluation of phosphatidylserine with omega-3 in non-demented older adults, and no serious drug interaction is established at normal supplement doses. Every remaining caution routes away from this dimension: soy allergy is an allergen property of one source material, anticoagulant co-use is drug-interaction-mediated and excluded by SM-024, athlete contamination risk is extrinsic under SM-055, and insufficient pregnancy data is a narrow excluded population. SM-074 does not apply, because the human safety database exists.
Side effects (Low): Phosphatidylserine side effects are mild, self-limiting and common enough to name, which is the second band. The reported complaints are nausea, stomach upset and loose stool, concentrated at the 600 to 800 mg per day stress and exercise protocols rather than the 300 mg cognition dose, plus insomnia or vivid dreams when phosphatidylserine is taken late because it shifts stress-hormone timing. Both resolve on dose reduction or earlier dosing. Phosphatidylserine does not reach the gut-cluster band above because no sourced incidence figure places these complaints in a meaningful minority, and soy-allergen exposure is avoidable by choosing sunflower-derived product.
Cost premium (Low): Phosphatidylserine is an ordinary ongoing supplement cost at its cheapest legitimate channel, which is the commodity band. A 300 mg/day cognition protocol runs 20 to 50 dollars a month from reputable brands, and the 600 to 800 mg/day cortisol protocols reach 40 to 90 dollars. This dimension measures premium over the cheapest legitimate route to the same exposure, and for phosphatidylserine no cheaper route exists: egg yolk, soy lecithin, white beans, mackerel and organ meats supply roughly 100 to 200 mg a day, which the packet says cannot reproduce trial dosing. The bovine-versus-soy mismatch is an evidence problem, not a price premium.
Effort (Negligible): Phosphatidylserine is effectively passive. Most phosphatidylserine protocols are one to three capsules taken daily with food, with no device, no appointment, no training curve and no lifestyle disruption, which is the ladder's bottom band for anything under a minute a day. The only genuine friction is matching dose to goal, roughly 300 mg daily for memory, 400 mg for stress reactivity and 600 mg for short exercise-cortisol blocks, and committing to a fixed eight-to-twelve-week window before judging, since phosphatidylserine effects are subtle enough that people quit early. Timing matters only in that late high doses can disturb sleep.
Opportunity cost (Low): Phosphatidylserine faces concrete, better-evidenced and cheaper alternatives in exactly the same category, which is the band where a stronger validated option already exists. The packet names them directly: omega-3, creatine, magnesium, sleep consistency, strength training and stress-management protocols all compete for the same budget and attention, and for a healthy young adult chasing a nootropic edge phosphatidylserine loses that comparison. The source-translation gap compounds the cost, because a soy product bought on the strength of bovine-cortex effect sizes is misallocation twice over. The opportunity falls sharply when the older-memory or high-cortisol phenotype genuinely matches.
Dependency (Negligible): Phosphatidylserine has no physiological dependency, no craving, no tolerance escalation and no withdrawal syndrome, and the packet records no evidence that cortisol rebounds above baseline after stopping phosphatidylserine. The benefit being maintenance-dependent is assigned to Durability by the ladder and is explicitly excluded here, which is the correction this score applies: plain need-to-keep-taking-it belongs at the floor, not at the functional-dependency anchor. Stopping phosphatidylserine carries no rebound penalty and no discontinuation symptoms, so the practical question is adherence rather than breaking a habit. That places phosphatidylserine in the bottom band alongside other benign supplements.
Reversibility (Negligible): Phosphatidylserine washes out completely with no named exception, which is the ladder's cleanest band. The packet states plasma phosphatidylserine normalises within days of stopping as phospholipid pools turn over, and there is no surgery, no implant, no permanent receptor change and no evidence of enduring gene-expression effects at nutritional dosing. That makes an eight-to-twelve-week phosphatidylserine trial genuinely low-stakes to abandon, and it means the source-translation risk costs nothing durable to test. Loss of the cognitive or cortisol benefit on stopping is scored under Durability and never here, and the tolerability complaints resolve rather than persisting.
Is Phosphatidylserine worth it?
Phosphatidylserine is a 7.0–7.5/10 fit for cognition focus, memory, stress resilience, especially for readers who can match the protocol to cortisol pattern, cognitive baseline, training stress, and soy or sunflower source. The best evidence anchors are Duan et al. 2025, which 190 randomized MCI patients; positive cognitive findings from a multi-ingredient formula, so PS-specific attribution is not separable, and Friling et al. 2025, which 209 randomized healthy children; no total-cohort primary or secondary outcome differences; subgroup signal for lower baseline cognitive performance. Phosphatidylserine is a targeted phospholipid supplement with its best evidence in older adults with memory complaints and stress-linked cortisol regulation.
✅ Best for: Adults 55+ with age-associated memory complaints who want a low-risk 300 mg/day trial and understand that the strongest evidence comes from older BC-PS trials, not necessarily the sunflower or soy PS bottle on today's shelf. Chronically stressed adults with high cortisol tone who want an HPA-axis support tool. Athletes in heavy blocks testing 600 mg/day for exercise-cortisol modulation per Starks 2008. Children with ADHD-like inattention only as an adjunct under clinician oversight, especially when omega-3 status is addressed.
❌ Avoid if: You are a young healthy adult without memory decline, high stress reactivity, ADHD-like inattention, or heavy training load. The expected cognitive upside is small and other interventions usually win. Avoid soy-derived PS if you have soy allergy; use sunflower PS instead. Avoid unsupervised pediatric use, pregnancy use, and anticoagulant or antiplatelet co-use without clinician input. Avoid PS as a dementia treatment substitute. FDA's claim is qualified and narrow, EFSA rejected a soy-PS cognition claim, and Alzheimer's Association experts do not currently recommend PS for Alzheimer's disease.
What is Phosphatidylserine best for?
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Cognition / Focus: 6.5/10
Score: 6.5/10For cognition focus, Phosphatidylserine lands at 6.5/10 because Friling et al. 2025 supports the core mechanism. FDA qualified claim status and older AAMI trials support targeted cognition use in elderly adults. Crook 1991 and Cenacchi 1993 are the main positive anchors, while Jorissen 2001 tempers modern S-PS expectations. The score stays bounded because Phosphatidylserine evidence for cognition focus can depend on cortisol pattern, cognitive baseline, training stress, and soy or sunflower source. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Memory: 6.5/10
Score: 6.5/10The memory use case earns 6.5/10 for Phosphatidylserine, anchored by Shen et al. 2026. Memory is the primary clinical endpoint for PS. Positive bovine cortex trials contrast with more mixed soy and sunflower data, including Kato-Kataoka 2010 subgroup findings and Friling 2025 largely null total-cohort results. The score stays bounded because Phosphatidylserine evidence for memory can depend on cortisol pattern, cognitive baseline, training stress, and soy or sunflower source. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Stress / Resilience: 6.5/10
Score: 6.5/10A 6.5/10 stress resilience rating fits Phosphatidylserine, since Monteleone et al. 1992 points to a real but bounded effect. Stress-resilience is the strongest non-cognitive use case. Hellhammer 2004 supports mental-stress modulation and Starks 2008 supports exercise-stress cortisol modulation. The score stays bounded because Phosphatidylserine evidence for stress resilience can depend on cortisol pattern, cognitive baseline, training stress, and soy or sunflower source. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Geriatric / Aging Population: 6.5/10
Score: 6.5/10The evidence-weighted call is 6.5/10 for Phosphatidylserine in geriatric, led by Starks et al. 2008. Older adults are the primary target population. Crook 1991 and Cenacchi 1993 support the core signal, while modern S-PS findings are smaller and less consistent. The score stays bounded because Phosphatidylserine evidence for geriatric can depend on cortisol pattern, cognitive baseline, training stress, and soy or sunflower source. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Pediatric Use: 6.0/10
Score: 6.0/10For readers tracking pediatric, Phosphatidylserine deserves 6.0/10 because Hellhammer et al. 2004 gives the strongest anchor. Pediatric evidence is meaningful but adjunctive. Manor 2012 tested PS-omega-3 in 200 children, Hirayama 2014 tested PS alone in a smaller trial, and Lee 2021 rated evidence low quality. The score stays bounded because Phosphatidylserine evidence for pediatric can depend on cortisol pattern, cognitive baseline, training stress, and soy or sunflower source. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Mood / Emotional Regulation: 5.5/10
Score: 5.5/10Phosphatidylserine scores 5.5/10 for mood, with the best signal coming from Duan et al. 2025. Mood signal is strongest in older adults and stressed users, with small elderly data from Maggioni 1990 plus HPA-axis studies. This is population-specific mood support, not broad antidepressant evidence. The score stays bounded because Phosphatidylserine evidence for mood can depend on cortisol pattern, cognitive baseline, training stress, and soy or sunflower source. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Recovery / Repair: 5.5/10
Score: 5.5/10Recovery Repair is a 5.5/10 fit for Phosphatidylserine, based on the evidence summarized in Crook et al. 1991. Starks 2008 supports cortisol moderation after exercise at 600 mg/day in a small crossover trial. Recovery benefit is hormonal and stress-load related, not direct tissue repair. The score stays bounded because Phosphatidylserine evidence for recovery repair can depend on cortisol pattern, cognitive baseline, training stress, and soy or sunflower source. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Hormonal / Endocrine: 5.5/10
Score: 5.5/10The practical hormonal read is 5.5/10 for Phosphatidylserine, with Cenacchi et al. 1993 setting the ceiling. Cortisol blunting is the most reproducible physiology signal outside cognition. Monteleone 1992, Hellhammer 2004, and Starks 2008 all support HPA-axis modulation. The score stays bounded because Phosphatidylserine evidence for hormonal can depend on cortisol pattern, cognitive baseline, training stress, and soy or sunflower source. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Neuroprotection: 5.0/10
Score: 5.0/10Evidence puts Phosphatidylserine at 5.0/10 for neuroprotection, mainly through Guo et al. 2024. PS supports neuronal membrane signaling and synaptic function, as reviewed by Kim 2014. Clinical dementia-prevention evidence is absent, so this remains mechanistic and adjacent to cognitive-aging data. The score stays bounded because Phosphatidylserine evidence for neuroprotection can depend on cortisol pattern, cognitive baseline, training stress, and soy or sunflower source. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Sleep Quality: 5.0/10
Score: 5.0/10Phosphatidylserine reaches 5.0/10 for sleep quality when the goal matches the population in Maggioni et al. 1990. The rationale is cortisol-timing dependent: lower evening HPA-axis overactivation may help some stressed users sleep, while late dosing can also cause insomnia. No dedicated sleep-quality RCT exists. The score stays bounded because Phosphatidylserine evidence for sleep quality can depend on cortisol pattern, cognitive baseline, training stress, and soy or sunflower source. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
| Use Case | Score | Summary |
|---|---|---|
| ○ Depression | 4.5 | Elderly mood benefits appear as secondary outcomes in older cognitive trials such as Maggioni 1990 and Cenacchi 1993. PS is not studied as a primary depression treatment. |
| ○ Anxiety | 4.5 | HPA-axis modulation is relevant to anxiety, and Hellhammer 2004 supports reduced endocrine stress response. There are no dedicated anxiety-disorder RCTs, so the score stays modest. |
| ○ Healthspan | 4.0 | Cognitive aging is a core healthspan domain, and PS has targeted evidence in older adults with memory complaints. The rating stays moderate because guideline bodies remain cautious. |
| ○ Neuroplasticity | 4.0 | PS supports PKC-mediated membrane signaling and synaptic function, with clinical support only indirectly through memory trials. This is relevant but not a direct neuroplasticity endpoint. |
| ○ Longevity / Lifespan | 3.0 | Membrane integrity and cortisol regulation are aging-relevant, but no lifespan, mortality, or long-term disease-prevention RCTs support PS as a longevity intervention. |
| ○ HRV / Vagal Tone / Autonomic Balance | 3.0 | Cortisol reduction could support vagal tone, but no direct HRV RCTs for PS were verified. |
Compare Phosphatidylserine with
Frequently Asked Questions
What is the difference between S-PS and BC-PS?
BC-PS was the bovine cortex form used in classic memory trials like Crook 1991 and Cenacchi 1993. It was DHA-rich and closer to brain PS composition. Modern S-PS is soy or sunflower-derived, safer commercially after BSE concerns, and usually linoleic-acid-rich. That likely matters: Jorissen 2001 found no significant cognition benefit from soy-derived PS in 120 older adults.
Why does PS have an FDA qualified health claim but not EFSA approval?
FDA allows a narrow qualified health claim for phosphatidylserine and reduced risk of cognitive dysfunction in the elderly, but this is not drug approval. The FDA claim appears on its qualified health claims letters page and requires cautious wording. EFSA reviewed soy-derived PS and rejected the cognition claim in its scientific opinion, while the Alzheimer's Association is also cautious. The practical read: credible but not conclusive evidence.
How does phosphatidylserine blunt cortisol?
Phosphatidylserine appears to modulate HPA-axis feedback, lowering ACTH and cortisol responses to stress in selected protocols. Monteleone 1992 found blunted exercise-induced ACTH and cortisol after chronic bovine PS. Hellhammer 2004 used a soy lecithin phosphatidic acid and PS complex during mental stress. Starks 2008 found lower peak cortisol after 600 mg/day for 10 days in healthy men.
What is the evidence for phosphatidylserine in ADHD?
Pediatric ADHD evidence is promising but still adjunctive. Manor 2012 tested PS-omega-3 in 200 children and found symptom improvements in selected scales and subgroups. Hirayama 2014 tested PS alone in a smaller trial and reported memory and inattention improvements. Lee 2021 found a significant inattention signal across RCTs but rated the evidence low quality. PS does not replace first-line ADHD care.
What dose of phosphatidylserine works for cognition vs. cortisol?
Use 300 mg/day for cognition and 400-800 mg/day for stress or exercise cortisol protocols. The older memory trials used 300 mg/day, including Crook 1991 and Cenacchi 1993. Stress protocols differ: Hellhammer 2004 used a 400 mg/day PAS complex, while Starks 2008 used 600 mg/day. Take PS with food and avoid late dosing if it worsens sleep.
Does phosphatidylserine work in young healthy people?
PS is weak as a general nootropic for healthy young people. The best-supported responders have age-related memory complaints, high stress reactivity, ADHD-like inattention, or heavy training stress. The 2025 Friling healthy-child RCT found no primary or secondary outcome differences in the total cohort, with only subgroup signals. That fits the broader pattern: PS is compensatory, not a universal cognitive enhancer.
Is phosphatidylserine safe?
PS has a favorable safety profile at nutritional doses. Cenacchi 1993 reported good tolerability across 6 months in a large older-adult trial, and Vakhapova 2011 specifically evaluated PS-DHA safety in non-demented elderly. Main issues are mild GI upset, insomnia from high evening doses, soy allergy for soy-derived products, insufficient pregnancy data, and theoretical caution with anticoagulants. Athletes should use third-party tested products.
How long does it take for phosphatidylserine to work?
Timeline depends on the endpoint. Exercise cortisol changes appeared after 10 days in Starks 2008. Mental-stress protocols usually evaluate after 2-3 weeks, as in Hellhammer 2004. Memory trials generally need 6-12+ weeks, and ADHD trials ran 8-15 weeks. After stopping, benefits fade because PS is a maintenance supplement, not a permanent remodeling intervention.
Should I take phosphatidylserine with omega-3?
Pairing PS with DHA is a reasonable strategy when cognition is the goal. The old bovine cortex form was DHA-rich, while modern soy and sunflower PS are usually not. Vakhapova 2010 tested PS-DHA in non-demented elderly with memory complaints, and Manor 2012 used PS-omega-3 in children with ADHD. This does not prove that any fish-oil stack works, but it is the most coherent modern approximation.
What could change Phosphatidylserine's score?
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimensions changed | New score |
|---|---|---|
| Large independent RCT confirms sunflower PS plus DHA replicates older BC-PS memory benefits in adults 55+ | Efficacy 3.2 to 4.0; Evidence 3.5 to 4.0 | 7.6 / 10 💪 Strong recommend |
| Cochrane review concludes PS has consistent cognitive benefit in age-associated memory impairment | Evidence 3.5 to 4.2; Bioindividuality 3.0 to 3.5 | 7.3 / 10 💪 Strong recommend |
| EFSA approves a revised cognition claim for soy or sunflower PS | Evidence 3.5 to 4.0 | 7.2 / 10 💪 Strong recommend |
| Additional large healthy-child and healthy-young-adult RCTs remain null | Efficacy 3.2 to 2.8; Breadth 3.6 to 3.2 | 7.0 / 10 💪 Strong recommend |
| Study shows cortisol rebound above baseline after PS cessation | Dependency 1.5 to 2.5; Reversibility 1.1 to 2.0 | 6.3 / 10 👍 Worth trying |
| Clean non-bovine DHA-rich PS becomes available and shows strong safety plus cognitive replication | Efficacy 3.2 to 3.8; Evidence 3.5 to 4.0 | 7.5 / 10 💪 Strong recommend |
Key Evidence Sources
- Duan et al. 2025 - Effects of a food supplement containing phosphatidylserine on cognitive function in Chinese older adults with mild cognitive impairment, Journal of Affective Disorders. 190 randomized MCI patients; positive cognitive findings from a multi-ingredient formula, so PS-specific attribution is not separable.
- Friling et al. 2025 - The cognitive effects of supplementation with sunflower phosphatidyl serine in healthy children aged 8 to 12 years, Nutrition Journal. 209 randomized healthy children; no total-cohort primary or secondary outcome differences; subgroup signal for lower baseline cognitive performance.
- Shen et al. 2026 - The effect of phosphatidylserine on behavioral problems in children with attention deficit hyperactivity disorder, Frontiers in Psychiatry. Open-label randomized comparison in 56 children; PS did not significantly improve core ADHD symptoms while atomoxetine did.
- Guo et al. 2024 - Phosphatidylserine: A Novel Target for Ischemic Stroke Treatment, Biomolecules. Narrative/translational review of PS biology in ischemic stroke; mechanism source, not oral supplement efficacy evidence.
- Crook et al. 1991 - Effects of phosphatidylserine in age-associated memory impairment, Neurology. 149 AAMI patients; bovine cortex PS 300 mg/day for 12 weeks improved learning and memory-related performance versus placebo.
- Cenacchi et al. 1993 - Cognitive decline in the elderly: double-blind placebo-controlled multicenter trial of phosphatidylserine, Aging. 494 older adults; 300 mg/day for 6 months improved behavioral and cognitive measures with good tolerability.
- Maggioni et al. 1990 - Effects of phosphatidylserine therapy in geriatric patients with depressive disorders, Acta Psychiatrica Scandinavica. Small elderly female sample; mood, memory, and behavior signal. v0 sample-size language was corrected downward.
- Monteleone et al. 1992 - Blunting by chronic phosphatidylserine administration of stress-induced HPA-axis activation in healthy men, European Journal of Clinical Pharmacology. 9 healthy men; chronic bovine PS 800 mg/day blunted ACTH and cortisol responses to exercise stress.
- Hellhammer et al. 2004 - Effects of soy lecithin phosphatidic acid and phosphatidylserine complex on endocrine and psychological responses to mental stress, Stress. Mental-stress study using PAS complex; supports stress-reactivity framing but not PS-alone attribution.
- Starks et al. 2008 - The effects of phosphatidylserine on endocrine response to moderate intensity exercise, Journal of the International Society of Sports Nutrition. 10 healthy men crossover; 600 mg/day for 10 days reduced peak cortisol and cortisol exposure during exercise stress.
- Jorissen et al. 2001 - The influence of soy-derived phosphatidylserine on cognition in age-associated memory impairment, Nutritional Neuroscience. 120 older adults; 300 or 600 mg/day soy-derived PS showed no significant cognitive benefit versus placebo.
- Kato-Kataoka et al. 2010 - Soybean-derived phosphatidylserine improves memory function of elderly Japanese subjects with memory complaints, Journal of Clinical Biochemistry and Nutrition. 78 older adults; no broad between-group signal, but memory improvements in lower-baseline subgroup.
- Vakhapova et al. 2010 - Phosphatidylserine containing omega-3 fatty acids may improve memory abilities in non-demented elderly with memory complaints, Dementia and Geriatric Cognitive Disorders. 157 older adults; PS-DHA improved verbal immediate recall and subgroup memory outcomes.
- Vakhapova et al. 2011 - Safety of phosphatidylserine containing omega-3 fatty acids in non-demented elderly, BMC Neurology. Safety extension and tolerability evidence for PS-DHA in elderly participants with memory complaints.
- Manor et al. 2012 - PS-omega-3 in children with ADHD symptoms, European Psychiatry. 200 children; double-blind phase plus extension; benefits concentrated in selected scales and subgroups.
- Hirayama et al. 2014 - Phosphatidylserine administration on memory and ADHD symptoms, Journal of Human Nutrition and Dietetics. Small pediatric RCT; PS improved memory and inattention-related outcomes.
- Lee et al. 2021 - Phosphatidylserine for pediatric ADHD: systematic review and meta-analysis, Journal of Alternative and Complementary Medicine. Four studies narrative review; three RCTs in meta-analysis; inattention signal, overall evidence quality low.
- Kim et al. 2014 - Phosphatidylserine in the brain: metabolism and function, Progress in Lipid Research. Mechanistic review of brain PS metabolism, DHA-rich PS, synaptic function, and membrane signaling.
- Ma et al. 2022 - Phosphatidylserine, inflammation, and central nervous system diseases, Frontiers in Aging Neuroscience. Mechanistic CNS review; useful for neuroinflammation context, not oral supplement efficacy.
- FDA - Qualified Health Claims Letters of Enforcement Discretion. Official source for phosphatidylserine cognitive-function qualified health claim letters.
- EFSA Panel NDA 2011 - Scientific opinion on phosphatidylserine and cognitive function. EFSA did not approve the soy-derived PS cognition health claim due to insufficient cause-and-effect evidence.
- Alzheimer's Association - Alternative Treatments. Cautious society position: early bovine-source promise, soy-source uncertainty, experts do not currently recommend PS for Alzheimer's disease.
- WADA - Prohibited List. Phosphatidylserine is not listed as a named prohibited substance; supplement contamination risk still applies.
What does the evidence say about Phosphatidylserine?
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Medium
Citations: Friling 2025, Duan 2025, Shen 2026, Jorissen 2001, Kato-Kataoka 2010, Vakhapova 2010, Lee 2021, Starks 2008
Pre-RCT-Era Pharmacology and Use
Confidence: Medium
Citations: Crook 1991, Cenacchi 1993, Maggioni 1990, FDA 2003 qualified claim
Traditional Medicine Systems
Confidence: Low
Holistic Evidence for Phosphatidylserine
All lenses point in the same direction but with different strength. Modern trials show targeted benefit in older adults, stress physiology, and pediatric inattention, while also showing null results in healthier or broader cohorts. Historical evidence explains why early bovine cortex results may not fully transfer to modern soy or sunflower PS. Traditional food patterns support phospholipid intake, not high-dose isolated PS. The honest synthesis: phosphatidylserine is useful when baseline need exists, but it is not a universal brain supplement.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- Cortisol AM Baseline (pre-protocol) During | Expected Down
- ALT During | Expected Stable
Pulse Dimensions to Watch
- Calm During | Expected Up | Primary
- Sleep During | Expected Up | Secondary
- Drive During | Expected Up | Secondary
Subjective Signals (Daily Voice Card)
- Stress Reactivity Scale 1-5 | During | Expected Down
- Memory Recall Scale 1-5 | During | Expected Up
- Sleep Quality Scale 1-5 | During | Expected Up
Red Flags: Stop and Consult
- Excess sedation
- New insomnia or vivid dreams
Other interventions for Cognition & Focus
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–2.9, Caution 3.0–4.4, Neutral 4.5–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–8.7, Top-tier 8.8–10.0.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 2.115 − 0.475 = 1.640
Formula v2.0 maps EV = 0 to score 5.0. Above neutral, EV = +4.00 reaches 10.0; below neutral, EV = −5.36 reaches 0.0. Both sides use the full 5-point half-scale.
Score = 5 + (1.640 / 4.00) × 5 = 7.1 / 10
